RP9P and neoplasm: Furthermore, miR‐133a‐3p downregulation counteracted the tumor‐suppressive effects of RP9P knockdown, highlighting the RP9P/miR‐133a‐3p/FOXQ1 axis as a critical pathway in CRC progression [40].